ALKERMES PLC (ALKS) Fundamental Analysis & Valuation

NASDAQ:ALKS • IE00B56GVS15

27.74 USD
-0.71 (-2.5%)
At close: Mar 10, 2026
27.74 USD
0 (0%)
After Hours: 3/10/2026, 8:05:49 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This ALKS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to ALKS. ALKS was compared to 519 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making ALKS a very profitable company, without any liquidiy or solvency issues. ALKS has a correct valuation and a medium growth rate. These ratings could make ALKS a good candidate for quality investing.


Dividend Valuation Growth Profitability Health

7

1. ALKS Profitability Analysis

1.1 Basic Checks

  • In the past year ALKS was profitable.
  • In the past year ALKS had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: ALKS reported negative net income in multiple years.
  • ALKS had a positive operating cash flow in each of the past 5 years.
ALKS Yearly Net Income VS EBIT VS OCF VS FCFALKS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

1.2 Ratios

  • With an excellent Return On Assets value of 9.72%, ALKS belongs to the best of the industry, outperforming 93.64% of the companies in the same industry.
  • ALKS has a Return On Equity of 13.28%. This is amongst the best in the industry. ALKS outperforms 93.83% of its industry peers.
  • ALKS's Return On Invested Capital of 10.90% is amongst the best of the industry. ALKS outperforms 94.41% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for ALKS is in line with the industry average of 19.44%.
  • The 3 year average ROIC (18.21%) for ALKS is well above the current ROIC(10.90%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 9.72%
ROE 13.28%
ROIC 10.9%
ROA(3y)14.74%
ROA(5y)6.76%
ROE(3y)22.64%
ROE(5y)9.68%
ROIC(3y)18.21%
ROIC(5y)N/A
ALKS Yearly ROA, ROE, ROICALKS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20

1.3 Margins

  • ALKS has a better Profit Margin (16.37%) than 92.49% of its industry peers.
  • With an excellent Operating Margin value of 17.21%, ALKS belongs to the best of the industry, outperforming 93.45% of the companies in the same industry.
  • Looking at the Gross Margin, with a value of 86.69%, ALKS belongs to the top of the industry, outperforming 88.63% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ALKS has remained more or less at the same level.
Industry RankSector Rank
OM 17.21%
PM (TTM) 16.37%
GM 86.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.55%
GM growth 5Y0.92%
ALKS Yearly Profit, Operating, Gross MarginsALKS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. ALKS Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so ALKS is creating value.
  • The number of shares outstanding for ALKS has been increased compared to 1 year ago.
  • ALKS has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for ALKS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ALKS Yearly Shares OutstandingALKS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
ALKS Yearly Total Debt VS Total AssetsALKS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.2 Solvency

  • ALKS has an Altman-Z score of 5.45. This indicates that ALKS is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of ALKS (5.45) is better than 73.03% of its industry peers.
  • There is no outstanding debt for ALKS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 5.45
ROIC/WACC1.42
WACC7.7%
ALKS Yearly LT Debt VS Equity VS FCFALKS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

2.3 Liquidity

  • A Current Ratio of 3.55 indicates that ALKS has no problem at all paying its short term obligations.
  • ALKS has a Current ratio (3.55) which is comparable to the rest of the industry.
  • A Quick Ratio of 3.19 indicates that ALKS has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 3.19, ALKS is doing worse than 61.08% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.55
Quick Ratio 3.19
ALKS Yearly Current Assets VS Current LiabilitesALKS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. ALKS Growth Analysis

3.1 Past

  • The earnings per share for ALKS have decreased strongly by -40.76% in the last year.
  • ALKS shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 31.92% yearly.
  • The Revenue has decreased by -5.25% in the past year.
  • The Revenue has been growing slightly by 7.28% on average over the past years.
EPS 1Y (TTM)-40.76%
EPS 3Y71.6%
EPS 5Y31.92%
EPS Q2Q%-72.38%
Revenue 1Y (TTM)-5.25%
Revenue growth 3Y9.9%
Revenue growth 5Y7.28%
Sales Q2Q%-10.57%

3.2 Future

  • The Earnings Per Share is expected to grow by 31.80% on average over the next years. This is a very strong growth
  • ALKS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.16% yearly.
EPS Next Y-135.86%
EPS Next 2Y-28.08%
EPS Next 3Y-2.65%
EPS Next 5Y31.8%
Revenue Next Year21.99%
Revenue Next 2Y12.92%
Revenue Next 3Y10.71%
Revenue Next 5Y11.16%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ALKS Yearly Revenue VS EstimatesALKS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B
ALKS Yearly EPS VS EstimatesALKS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

5

4. ALKS Valuation Analysis

4.1 Price/Earnings Ratio

  • ALKS is valuated correctly with a Price/Earnings ratio of 16.13.
  • Based on the Price/Earnings ratio, ALKS is valued cheaper than 94.61% of the companies in the same industry.
  • ALKS is valuated rather cheaply when we compare the Price/Earnings ratio to 26.25, which is the current average of the S&P500 Index.
  • ALKS is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 16.13
Fwd PE N/A
ALKS Price Earnings VS Forward Price EarningsALKS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ALKS is valued cheaper than 94.99% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of ALKS indicates a rather cheap valuation: ALKS is cheaper than 97.88% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 9.62
EV/EBITDA 14.06
ALKS Per share dataALKS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

  • The decent profitability rating of ALKS may justify a higher PE ratio.
  • A cheap valuation may be justified as ALKS's earnings are expected to decrease with -2.65% in the coming years.
PEG (NY)N/A
PEG (5Y)0.51
EPS Next 2Y-28.08%
EPS Next 3Y-2.65%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALKS Dividend Analysis

5.1 Amount

  • No dividends for ALKS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALKS Fundamentals: All Metrics, Ratios and Statistics

ALKERMES PLC

NASDAQ:ALKS (3/10/2026, 8:05:49 PM)

After market: 27.74 0 (0%)

27.74

-0.71 (-2.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)04-29
Inst Owners109.8%
Inst Owner Change2.03%
Ins Owners1.6%
Ins Owner Change5.8%
Market Cap4.62B
Revenue(TTM)1.48B
Net Income(TTM)241.66M
Analysts81.67
Price Target44.69 (61.1%)
Short Float %10.94%
Short Ratio9.08
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)21.45%
Min EPS beat(2)-16.95%
Max EPS beat(2)59.84%
EPS beat(4)3
Avg EPS beat(4)31.82%
Min EPS beat(4)-16.95%
Max EPS beat(4)72.36%
EPS beat(8)4
Avg EPS beat(8)15.4%
EPS beat(12)7
Avg EPS beat(12)24.7%
EPS beat(16)10
Avg EPS beat(16)139.34%
Revenue beat(2)1
Avg Revenue beat(2)3.48%
Min Revenue beat(2)-1.55%
Max Revenue beat(2)8.51%
Revenue beat(4)2
Avg Revenue beat(4)4.47%
Min Revenue beat(4)-1.55%
Max Revenue beat(4)12.13%
Revenue beat(8)3
Avg Revenue beat(8)2.64%
Revenue beat(12)6
Avg Revenue beat(12)3.42%
Revenue beat(16)9
Avg Revenue beat(16)2.75%
PT rev (1m)0%
PT rev (3m)-0.14%
EPS NQ rev (1m)-491.83%
EPS NQ rev (3m)-616.77%
EPS NY rev (1m)-141.15%
EPS NY rev (3m)-140.46%
Revenue NQ rev (1m)2.72%
Revenue NQ rev (3m)-0.54%
Revenue NY rev (1m)-0.87%
Revenue NY rev (3m)-1.66%
Valuation
Industry RankSector Rank
PE 16.13
Fwd PE N/A
P/S 3.13
P/FCF 9.62
P/OCF 8.88
P/B 2.54
P/tB 2.66
EV/EBITDA 14.06
EPS(TTM)1.72
EY6.2%
EPS(NY)-0.62
Fwd EYN/A
FCF(TTM)2.88
FCFY10.39%
OCF(TTM)3.12
OCFY11.26%
SpS8.86
BVpS10.92
TBVpS10.41
PEG (NY)N/A
PEG (5Y)0.51
Graham Number20.55
Profitability
Industry RankSector Rank
ROA 9.72%
ROE 13.28%
ROCE 13.07%
ROIC 10.9%
ROICexc 15.63%
ROICexgc 16.66%
OM 17.21%
PM (TTM) 16.37%
GM 86.69%
FCFM 32.55%
ROA(3y)14.74%
ROA(5y)6.76%
ROE(3y)22.64%
ROE(5y)9.68%
ROIC(3y)18.21%
ROIC(5y)N/A
ROICexc(3y)43.15%
ROICexc(5y)N/A
ROICexgc(3y)50.12%
ROICexgc(5y)N/A
ROCE(3y)21.84%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.55%
GM growth 5Y0.92%
F-Score6
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 148.79%
Cap/Sales 2.74%
Interest Coverage 250
Cash Conversion 185.24%
Profit Quality 198.76%
Current Ratio 3.55
Quick Ratio 3.19
Altman-Z 5.45
F-Score6
WACC7.7%
ROIC/WACC1.42
Cap/Depr(3y)110.09%
Cap/Depr(5y)83%
Cap/Sales(3y)2.59%
Cap/Sales(5y)2.72%
Profit Quality(3y)136.19%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-40.76%
EPS 3Y71.6%
EPS 5Y31.92%
EPS Q2Q%-72.38%
EPS Next Y-135.86%
EPS Next 2Y-28.08%
EPS Next 3Y-2.65%
EPS Next 5Y31.8%
Revenue 1Y (TTM)-5.25%
Revenue growth 3Y9.9%
Revenue growth 5Y7.28%
Sales Q2Q%-10.57%
Revenue Next Year21.99%
Revenue Next 2Y12.92%
Revenue Next 3Y10.71%
Revenue Next 5Y11.16%
EBIT growth 1Y-39.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year50.82%
EBIT Next 3Y26.72%
EBIT Next 5Y26.75%
FCF growth 1Y18.41%
FCF growth 3YN/A
FCF growth 5Y63.91%
OCF growth 1Y18.59%
OCF growth 3Y191.61%
OCF growth 5Y44.45%

ALKERMES PLC / ALKS FAQ

What is the fundamental rating for ALKS stock?

ChartMill assigns a fundamental rating of 6 / 10 to ALKS.


What is the valuation status of ALKERMES PLC (ALKS) stock?

ChartMill assigns a valuation rating of 5 / 10 to ALKERMES PLC (ALKS). This can be considered as Fairly Valued.


Can you provide the profitability details for ALKERMES PLC?

ALKERMES PLC (ALKS) has a profitability rating of 7 / 10.


Can you provide the expected EPS growth for ALKS stock?

The Earnings per Share (EPS) of ALKERMES PLC (ALKS) is expected to decline by -135.86% in the next year.